Zymeworks achieves $14M milestone under GSK deal
Zymeworks (NASDAQ:ZYME) said it has achieved a $14M cash research milestone through its collaboration with GSK (GSK). Under ...
Jazz Pharmaceuticals: Decent 2025 Outlook, Extended Timeline For Zanidatamab
Jazz Pharmaceuticals ended 2024 on a strong note, beating analyst estimates. I continue to see Jazz stock as a valuation ...
Zymeworks achieves $14M milestone from GSK
Zymeworks (ZYME) announced achievement of a $14M cash research milestone from GSK (GSK) associated with a clinical milestone. “In April 2016, ...
Zymeworks Announces Achievement of $14 Million Milestone from GSK Collaboration
Clinical validation of the Azymetric platform is demonstrated by the accelerated approval of Ziihera® (zanidatamab-hrii), a treatment for advanced HER2-positive biliary tract cancer in adults who have ...
Zymeworks Inc.: Zymeworks Announces Achievement of $14 Million Milestone from GSK Collaboration
Zymeworks Inc. (Nasdaq: ZYME) a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics ...
港股概念追踪|百济神州成为国内“创新药一哥” 机构看好创新药2025 ...
国泰君安研报表示，当前头部创新药企研发&销售体系成熟，费用增长稳健，伴随核心产品商业化持续放量，多家企业扭亏节点临近，创新迎来收获期。重点关注产品差异化优势显著、创新属性较高的细分龙头。